Silexion Therapeutics Ltd. (SLXN) Gamma Exposure (GEX) & Greeks

Gamma exposure (GEX) analysis shows how options positioning creates dealer hedging pressure across strikes. Includes delta, vanna, charm, vomma, and vega exposure by strike price.

Silexion Therapeutics Ltd. (SLXN) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $280,482, listed on NASDAQ, employing roughly 11 people, carrying a beta of -0.29 to the broader market. Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. Led by Ilan Hadar, public since 2024-08-16.

Greeks exposure analysis shows dealer hedging pressure across strike prices for all six Greeks. No recent options activity for SLXN as of 2026-06-02; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.

Learn how gamma exposure is reported and how to read the data →